| Literature DB >> 21637432 |
Wender Ferreira Costa1, Alaide Braga de Oliveira, Júlio César Nepomuceno.
Abstract
This study investigated the genotoxicity of Lapachol (LAP) evaluated by wing spot test of Drosophila melanogaster in the descendants from standard (ST) and high bioactivation (HB) crosses. This assay detects the loss of heterozygosity of marker genes expressed phenotypically on the fly's wings. Drosophila has extensive genetic homology to mammals, which makes it a suitable model organism for genotoxic investigations. Three-day-old larvae from ST crosses (females flr(3)/TM3, Bd(s) x males mwh/mwh), with basal levels of the cytochrome P450 and larvae of high metabolic bioactivity capacity (HB cross) (females ORR; flr(3)/TM3, Bd(s) x males mwh/mwh), were used. The results showed that LAP is a promutagen, exhibiting genotoxic activity in larvae from the HB cross. In other words, an increase in the frequency of spots is exclusive of individuals with a high level of the cytochrome P450. The results also indicate that recombinogenicity is the main genotoxic event induced by LAP.Entities:
Keywords: Drosophila melanogaster; SMART; cytochrome P450; doxorubicin; lapachol
Year: 2010 PMID: 21637432 PMCID: PMC3036112 DOI: 10.1590/S1415-47572010005000070
Source DB: PubMed Journal: Genet Mol Biol ISSN: 1415-4757 Impact factor: 1.771
Figure 1Chemical structures of LAP and DXR.
Summary of results in the Drosophila SMART assay after treatment with Lapachol (LAP). Larvae from Standard (ST) cross and High Bioactivation (HB) cross.
| Spots per fly (Nº of spots); stat. diagnosesa | ||||||||||
| Series | Small single spots
| Large single spots
| Twin
| Total spots
| Spots with | Mean clone size class | Frequency of clone formation per 105 cellsd | |||
| DXR (mg/mL) | LAP (μg/mL) | Nº of flies | (1-2 cells)b | (> 2 cells)b | Observed | Control corrected | ||||
| ST cross | ||||||||||
| 0 | 0 | 50 | 0.44 (22) | 0.08 (04) | 0.00 (00) | 0.52 (26) | 26 | 1.88 | 1.07 | |
| 0.125 | 0 | 50 | 0.84 (42) + | 0.52 (26) + | 0.52 (26) + | 1.88 (94) + | 68 | 2.49 | 2.79 | 2.86 |
| 0 | 20 | 60 | 0.52 (31) - | 0.08 (05) i | 0.00 (00) i | 0.60 (36) - | 36 | 1.83 | 1.23 | 0.16 |
| 0 | 40 | 60 | 0.32 (19) - | 0.07 (04) i | 0.02 (01) i | 0.40 (24) - | 23 | 2.04 | 0.79 | -0.28 |
| 0 | 60 | 60 | 0.35 (21) - | 0.10 (06) i | 0.03 (02) i | 0.48 (29) - | 27 | 2.11 | 0.92 | -0.14 |
| 0 | 0 | 50 | 0.04 (02) | 0.04 (02) | 0.08 (04) | 4 | 2.00 | 0.16 | ||
| 0.125 | 0 | 50 | 0.10 (05) i | 0.06 (03) i | 0.16 (08) i | 8 | 2.50 | 0.33 | 0.16 | |
| HB cross | ||||||||||
| 0 | 0 | 50 | 0.62 (31) | 0.04 (02) | 0.04 (02) | 0.70 (35) | 33 | 1.64 | 1.35 | |
| 0.125 | 0 | 50 | 2.04 (102) + | 0.22 (11) + | 0.32 (16) + | 2.58 (129) + | 113 | 1.64 | 4.63 | 3.28 |
| 0 | 20 | 60 | 0.93 (56) + | 0.10 (06) i | 0.02 (01) i | 1.05 (63) + | 62 | 1.55 | 2.12 | 0.77 |
| 0 | 40 | 60 | 1.08 (65) + | 0.13 (08) i | 0.07 (04) i | 1.28 (77) + | 73 | 1.70 | 2.49 | 1.14 |
| 0 | 60 | 60 | 1.25 (75) + | 0.10 (06) i | 0.05 (03) i | 1.40 (84) + | 81 | 1.54 | 2.77 | 1.41 |
| 0 | 0 | 50 | 0.44 (22) | 0.08 (04) | 0.52 (26) | 26 | 1.58 | 1.07 | ||
| 0.125 | 0 | 50 | 0.44 (22) - | 0.04 (02) i | 0.48 (24) - | 24 | 1.46 | 0.98 | -0.08 | |
| 0 | 20 | 50 | 0.30 (15) - | 0.04 (02) i | 0.34 (17) - | 17 | 1.29 | 0.70 | -0.37 | |
| 0 | 40 | 50 | 0.40 (20) - | 0.02 (01) - | 0.42 (21) - | 21 | 1.48 | 0.86 | -0.20 | |
| 0 | 60 | 50 | 0.40 (20) - | 0.00 (00) - | 0.40 (20) - | 20 | 1.20 | 0.82 | -0.25 | |
aStatistical diagnoses according to Frei and Würgler (1988): +, positive; -, negative; i, inconclusive; m, multiplication factor. Kastenbaum-Bowman tests, one sided. Probability levels α = β = 0.05. bIncluding rare flr single spots. cConsidering mwh clones from mwh single and twin spots. dFrequency of clone formation: clones/flies/48,800 cells (without size correction). DXR, doxorubicin; LAP, lapachol.